Seductive early trial results showed massive reductions in LDL cholesterol among patients who took PCSK9 inhibitors—the new injectable cholesterol-lowering medications—including those already taking high-intensity statin therapy. Now that they are on the market, physicians are coming to terms with how to best use the costly drugs in selective patients.
Read more at tctmd